Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 11:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Healthy
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 4,340 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 8
States / cities: La Jolla, California • San Francisco, California • Santa Monica, California + 5 more

Conditions: Degenerative Disc Disease
Interventions: Adipose Stem Cells; Procedure
Lead sponsor: Bioheart, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Sunrise, Florida

Conditions: Pancreatic Cancer
Interventions: Capecitabine, PHY906; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass
Interventions: catridecacog, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 35 Years to 70 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 15
States / cities: Tucson, Arizona • San Francisco, California • Denver, Colorado + 10 more

Conditions: Asthma
Interventions: albuterol sulfate inhalation aerosol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: Up to 23 Months
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 27
States / cities: Hoover, Alabama • Fort Mohave, Arizona • Jonesboro, Arkansas + 24 more

Conditions: Neoplasms, Prostatic Neoplasms
Interventions: cabazitaxel (XRP6258) (RPR116258), mitoxantrone, prednisone; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 755 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Atopic Dermatitis
Interventions: PF-04965842 200 mg, PF-04965842 100 mg, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 9
States / cities: Encinitas, California • Los Angeles, California • Largo, Florida + 5 more

Conditions: Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)
Interventions: Placebo, Enicepatide; Drug
Lead sponsor: Carmot Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 52
States / cities: Birmingham, Alabama • Guntersville, Alabama • Yuma, Arizona + 45 more

Conditions: Stress Urinary Incontinence
Interventions: Solyx Single Incision Sling System, Obtryx II Sling System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 22
States / cities: Beverly Hills, California • Loma Linda, California • San Diego, California + 18 more

Conditions: Asthma
Interventions: Mepolizumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 16
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 13 more

Conditions: COPD
Interventions: Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 10
States / cities: Clearwater, Florida • Tampa, Florida • Winter Park, Florida + 7 more

Conditions: Hypertension
Interventions: Aliskiren, Hydrochlorothiazide; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 532 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Nasal Septal Deviation, Nasal Airway Obstruction
Interventions: Implantation of Spirair Nasal Device using the Spirair delivery system.; Device
Lead sponsor: Spirair, Inc; Industry
Eligibility: 21 Years to 70 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Birmingham, Alabama • Torrance, California • Louisville, Kentucky + 5 more

Conditions: Arthroplasty, Replacement
Interventions: Investigational Arm: SMR Stemless Reverse, Control Arm: SMR Reverse Shoulder System; Device
Lead sponsor: Limacorporate S.p.a; Industry
Eligibility: 22 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 13
States / cities: Los Angeles, California • Denver, Colorado • Boca Raton, Florida + 9 more

Conditions: Dyspeptic Subjects
Interventions: 13C-uracil, 99mTc sulfur colloid; Drug
Lead sponsor: Otsuka Pharmaceutical Co., Ltd.; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Orlando, Florida • Lebanon, New Hampshire

Conditions: Neuropathic Corneal Pain
Interventions: Urcosimod ophthalmic solution is a preservative-free topical ophthalmic product; supplied in unit dose ampoules; administered QID for 12-weeks., Vehicle Ophthalmic Solution; Drug · Other
Lead sponsor: Okyo Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Acupuncture, Pain Management, Emergency Department, Acute Pain
Interventions: Acupuncture for pain management, Usual care for pain management; Procedure · Other
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 4
States / cities: La Jolla, California • The Bronx, New York • Cleveland, Ohio + 1 more

Conditions: Cardiovascular, Comorbidity, Diabetes, Inflammatory Joint Diseases, Chronic Kidney Diease, Chronic Obstructive Pulmonary Disease (COPD), Cardiovascular Disease
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 50 Years to 99 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Psoriatic Arthritis
Interventions: NDI-034858, Placebo; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 23
States / cities: Palm Desert, California • Upland, California • Hollywood, Florida + 19 more

Conditions: Duchenne Muscular Dystrophy
Interventions: Deflazacort; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 4 Years and older · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 4
States / cities: Los Angeles, California • Chicago, Illinois • Rochester, New York + 1 more

Conditions: Hodgkin's Lymphoma
Interventions: TGR-1202 + brentuximab vedotin; Drug
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: Duarte, California • San Diego, California • Sarasota, Florida + 1 more

Conditions: Overactive Bladder (OAB)
Interventions: Tensi+; Device
Lead sponsor: Stimuli Technology; Industry
Eligibility: 22 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Beverly Hills, California • New York, New York

Conditions: Atopic Dermatitis
Interventions: OPA-15406, Vehicle ointment; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 10 Years to 70 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 20
States / cities: Los Angeles, California • San Diego, California • Denver, Colorado + 17 more

Conditions: Multiple Sclerosis
Interventions: No Treatment Arm, Topical Preparation H arm; Other · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

BraveNet Integrative Medicine Descriptive Study

Adipose Cells for Degenerative Disc Disease

A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma

Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass

Inhaled Albuterol Sulfate For Acute Wheezing Due To Obstructive Airways Disease In Children

XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer

Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis

A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

Post Market Study Of Single Incision Sling Versus Transobturator Sling for Stress Urinary Incontinence

Study of Mepolizumab Autoinjector in Asthmatics

Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD

Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension

Open-Label Study to Evaluate the Safety and Effectiveness of the Spirair Implant

SMR Stemless Reverse vs SMR Reverse Shoulder System

Phase 2 Study to Evaluate the Preliminary Performance of the C13-URA Breath Test Kit in Dyspeptic Subjects

Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of Urcosimod Ophthalmic Solution in Participants With Neuropathic Corneal Pain (NCP).

Acupuncture in the Emergency Department for Pain Management

Improving Patient-Centered Care for Underserved Older African American Patients With Cardiovascular Comorbidities

A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis

An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability Deflazacort

Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients

Tensi+ for Treating Overactive Bladder

A Study to Evaluate the Effectiveness and Safety of Topical OPA-15406 Ointment to Treat Participants With Atopic Dermatitis

Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY